

## Company Overview:

### Intersect ENT

Intersect ENT, is an innovator in local drug delivery focused on advancing clinically proven therapy solutions that improve quality of life for ear, nose and throat patients.

The company's initial focus is a first-of-its-kind dissolvable steroid-releasing implant to treat patients with chronic sinusitis, a common condition that affects one out of seven adults in the U.S. and greatly impacts quality of life. PROPEL is the only product used in sinus surgery to be supported by level 1-A evidence.

The PROPEL™ Steroid-Releasing Implant is now commercially available as part of a limited release in select regions with plans to introduce the product more broadly in the U.S. over the next year.

The company holds seventeen issued U.S. patents and more than 75 patents and pending applications worldwide.

Based in Menlo Park, Calif., Intersect ENT employs approximately 70 people.

### Leadership Team

Lisa Earnhardt	President and Chief Executive Officer
Rich Kaufman	Senior Vice President and Chief Operating Officer
Monika De Martini	Chief Financial Officer
James Stambaugh	Vice President of Clinical and Reimbursement
Susan Stimson	Vice President of Marketing
Amy Wolbeck	Vice President of Regulatory Affairs and Quality

### Board of Directors

Lisa Earnhardt	Intersect ENT
Mark Fletcher	Medtronic, Inc.
Dana Mead	Kleiner, Perkins, Caufield & Byers
Rick Anderson	PTV Sciences
Fred Moll, M.D.	Restoration Robotics
Casey Tansey	U.S. Venture Partners (USVP)

### Investors

Intersect ENT has raised a total of approximately \$60 million from blue chip investors Kleiner, Perkins, Caufield & Byers; U.S. Venture Partners; PTV Sciences; and Medtronic.

### Corporate Headquarters

Intersect ENT, Inc.  
1555 Adams Drive  
Menlo Park, CA 94025  
650.641.2100

For more information please visit <http://www.intersectENT.com>.